Skip to Main Content

Carol and Gene Ludwig Program for the Study of Neuroimmune Interactions in Dementia

The Carol & Gene Ludwig Program for the Study of Neuroimmune Interactions in Dementia operates as a central home at Yale for the study of neurology, neuroscience, and immunobiology interactions as they relate to the dementias and specifically Alzheimer's. Alzheimer’s is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults.

About the Ludwig Program

The Carol & Gene Ludwig Program for the Study of Neuroimmune Interactions in Dementia will transform the field of neuroinflammation with the goal of identifying new pathways and interactions, facilitating fundamental discoveries across many platforms, and providing new nodes for therapeutic intervention.

Get Involved

Today, there are more than 55 million people worldwide living with dementia, seven million of whom are in the U.S. As of 2020, Alzheimer’s disease accounted for 60% of cases. There are currently no cures for Alzheimer’s or related disorders, and the urgency to develop effective treatments only grows. It is estimated that by 2050, Alzheimer’s will affect nearly 14 million people in the U.S. alone.

Ludwig Program Seminar Series

The Ludwig Program Seminar Series focuses on the topics of neuroimmunity, neuroinflammation, inflammation, dementia, and Alzheimer's disease, and is led by Yale and national leaders in these topics.